Sign In  |  Register  |  About Burlingame  |  Contact Us

Burlingame, CA
September 01, 2020 10:18am
7-Day Forecast | Traffic

  • Search Hotels in Burlingame

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Vertex Pharmaceuticals (NQ: VRTX )

471.12 -4.86 (-1.02%)
Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Vertex Pharmaceuticals

< Previous 1 2
...
19 20 21 22 23 24 25 26 27
...
53 54 Next >
Gene Therapy Breakthroughs On The Horizon
Vertex Pharmaceuticals and CRISPR Therapeutics, alongside bluebird bio, are penning a new chapter in the story of gene therapy for sickle cell disease. 
Via Talk Markets
Large Cap Biopharmaceuticals Performance 2023 YTD: Mixed Results But Lilly Is A Big Winner
Biotech stocks are in a bear market since the IBB hit $177.37 in 2021 and is down 7.84% over five years. 
Via Talk Markets
4 Superlative Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market Dip
With the Nasdaq Composite still 15% below its record-closing high, amazing deals are hiding in plain sight. 
Via The Motley Fool
Topics Stocks
Exposures US Equities
Peering Into Vertex Pharmaceuticals's Recent Short Interest
Via Benzinga
3 Monster Stocks to Buy Without Any Hesitation
You can rest easy investing in these great stocks. 
Via The Motley Fool
2 Excellent Stocks to Buy and Hold Forever
These companies have solid long-term potential. 
Via The Motley Fool
Is Vertex Pharmaceuticals Stock a Buy Now?
It's got upcoming catalysts, strong earnings, and a solid base of sales, too. 
Via The Motley Fool
Why CRISPR Therapeutics Stock Is Jumping Today
Analysts continue to like this gene-editing stock. 
Via The Motley Fool
3 Strong Biotech Performers To Watch As Sector Nears Breakout
As the IBB ETF nears a potential breakout, watch for strong performers like Regeneron Pharmaceuticals, Vertex, and Exelixis to continue outperforming. 
Via MarketBeat
Topics ETFs
The 3 Most Undervalued Biotech Stocks to Buy Now: August 2023
This article points you to three undervalued biotech stocks that have the potential to deliver stellar returns for patient investors. 
Via InvestorPlace
Vertex Pharmaceuticals Stock Shows Rising Relative Strength, Hits 80+
Vertex Pharmaceuticals shows improving price performance, earning an upgrade to its IBD Relative Strength Rating from 78 to 81. 
Via Investor's Business Daily
Here's How Much You Would Have Made Owning Vertex Pharmaceuticals Stock In The Last 10 Years
Via Benzinga
Missed Out on CRISPR Therapeutics? My Best Biotech Stock to Buy and Hold
CRISPR Therapeutics is an intriguing biotech stock to consider now. 
Via The Motley Fool
Analyst Expectations for Vertex Pharmaceuticals's Future
Via Benzinga
2 Top Biotech Stocks to Buy in August
Both companies are performing exceedingly well. 
Via The Motley Fool
This Is Arguably the Single Best Stock to Buy Right Now
This stock appears to be in a league of its own. 
Via The Motley Fool
Want to Get Richer? Buy and Hold These 5 Unstoppable Stocks
Buying these stocks and waiting should help you boost your personal wealth. 
Via The Motley Fool
Could Vertex Pharmaceuticals Stock Help You Become a Millionaire?
Vertex stock has been a growth beast in recent years -- can that trend continue? 
Via The Motley Fool
3 Explosive Stocks to Buy Right Now
These stocks are poised to pop in the not-too-distant future. 
Via The Motley Fool
3 Top Biotech Stocks Defying the Bear Market
Biotech is still booming, if you pick the right biotech stocks. 
Via The Motley Fool
2 Supercharged Growth Stocks That Could Make You Richer
These two biotechs are poised for a sustained period of growth. 
Via The Motley Fool
3 Top Healthcare Stocks to Buy for August
Shares of Humana, Vertex Pharmaceuticals, and Idexx Laboratories have all increased by at least 20% so far this year. 
Via The Motley Fool
Tech Leader Vertex Pharmaceuticals Beats And Raises, But Shares Inch Lower
The company ended the quarter with $12.6 billion in cash and equivalents. 
Via Investor's Business Daily
3 Fantastic Growth Stocks to Buy in August
These stocks could be poised to soar. 
Via The Motley Fool
Market Rally Under Pressure As Yields Soar; Amazon, ELF, Caterpillar Are Earnings Winners: Weekly Review
Amazon, ELF and CAT were earnings winners, but there were big losers too. 
Via Investor's Business Daily
2 Nasdaq 100 Stocks That Are Surefire Buys in August and 1 to Avoid
Two Nasdaq 100 components are plain-as-day bargains, while another Nasdaq 100 stock could struggle to live up to lofty expectations. 
Via The Motley Fool
Vertex Announces Publication of VX-548 Positive Phase 2, Proof-of-Concept Results in New England Journal of Medicine
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Vertex Pharma Raises Annual Forecast On Strong Uptake For Cystic Fibrosis Drug, Analysts Says Investors' Focus On Non-CF Pipeline
Vertex Pharmaceuticals Inc's (NASDAQ: VRTX) Q2 sales increased 14% to $2.49 billion, beating the consensus of $2.41 bill 
Via Benzinga
Vertex Pharmaceuticals (VRTX) Q2 2023 Earnings Call Transcript
VRTX earnings call for the period ending June 30, 2023. 
Via The Motley Fool
Vertex Reports Second Quarter 2023 Financial Results
From Vertex Pharmaceuticals Incorporated
Via Business Wire
< Previous 1 2
...
19 20 21 22 23 24 25 26 27
...
53 54 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 Burlingame.com & California Media Partners, LLC. All rights reserved.